Health ❯ Healthcare ❯ Clinical Research

Drug Development

Clinical Trials Eli Lilly Phase 2 Trials Phase 3 Trials Regulatory Approval Lecanemab Alzheimer's Treatments Medpace Holdings, Inc. Immunotherapy Trials Monoclonal Antibodies

6 ARTICLES

2w ago

FDA Approves Orzeyful as First Orexin Agonist for Narcolepsy Type 1

The oral, twice-daily pill directly activates the orexin receptor lost in the disorder, offering a new treatment approach likely to spur research into sleep disorders as well as other neurologic conditions.

7 ARTICLES

last mo.

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

3 ARTICLES

3mo ago

Design Therapeutics Reports Early DT-216P2 Data in Friedreich’s Ataxia

5 ARTICLES

4mo ago

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

3 ARTICLES

6mo ago

Alzheimer’s Study Finds Memory “Replay” Persists but Loses Structure

6 ARTICLES

7mo ago

Vulcan Value Partners' Q4 Letter Reports Gains, Deep Discounts and Portfolio Changes

3 ARTICLES

7mo ago

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

8 ARTICLES

7mo ago

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

3 ARTICLES

7mo ago

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models

3 ARTICLES

7mo ago

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

3 ARTICLES

8mo ago

Lilly’s Triple-Agonist Retatrutid Delivers About 29% Weight Loss in Phase 3, with Notable Side Effects

8 ARTICLES

9mo ago

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

4 ARTICLES

10mo ago

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

4 ARTICLES

11mo ago

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

5 ARTICLES

this yr.

Monthly Oral PrEP Candidate MK-8527 Shows Early Promise in Merck Study

5 ARTICLES

last yr.

Stanford Spray-Drying Method Could Turn Many IV Biologics Into Quick Injections

4 ARTICLES

last yr.

MHRA Licenses Teplizumab to Delay Onset of Type 1 Diabetes

Drug Development

FDA Approves Orzeyful as First Orexin Agonist for Narcolepsy Type 1

FDA Approves At‑Home Weekly Subcutaneous Starter Dose for Leqembi

FDA Grants Priority Review to Roche’s Enspryng for Thyroid Eye Disease

Turtle Creek Reports Q1 Loss and Active Rebalancing of Its Equity Fund

Sanofi Stops MOBILIZE Phase 3 Trial of Riliprubart in CIDP After Futility Finding

Design Therapeutics Reports Early DT-216P2 Data in Friedreich’s Ataxia

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Alzheimer’s Study Finds Memory “Replay” Persists but Loses Structure

Vulcan Value Partners' Q4 Letter Reports Gains, Deep Discounts and Portfolio Changes

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

Never miss stories about

Drug Development

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

Splice-Switching ASO Collapses Oncogenic Circuit in Pancreatic Cancer Models

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

Lilly’s Triple-Agonist Retatrutid Delivers About 29% Weight Loss in Phase 3, with Notable Side Effects

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Alector Ends Latozinemab After Phase 3 Failure, Slashes Workforce

Rapport Seizure Drug Posts Strong Phase 2 Signal as Company Plans Phase 3

Monthly Oral PrEP Candidate MK-8527 Shows Early Promise in Merck Study

Stanford Spray-Drying Method Could Turn Many IV Biologics Into Quick Injections

MHRA Licenses Teplizumab to Delay Onset of Type 1 Diabetes

Never miss stories about

Drug Development